Axovant Sciences Ltd. (AXON) Reports Q3 Loss Per Share of 64c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. JBHT
3. CRWV
4. SCHW
5. GPRK
6. TFC
7. USB
8. PNC
9. NEST:IN
10. AA

Go back to Axovant Sciences Ltd. (AXON) Reports Q3 Loss Per Share of 64c

Axovant Sciences Announces Launch of First-in-Class Clinical Programs for Lewy Body Dementia and Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2015

February 9, 2016 4:16 PM EST

HAMILTON, Bermuda, Feb. 9, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter. In addition, the Company reported financial results for the third fiscal quarter and nine months ended December 31,... More